San Martin R, Das P, Xue T, Brown M, Dos Reis Marques R, Essington M
Heliyon. 2025; 11(3):e41929.
PMID: 39931470
PMC: 11808503.
DOI: 10.1016/j.heliyon.2025.e41929.
Ishii K, Iguchi K, Matsuda C, Hirokawa Y, Sugimura Y, Watanabe M
J Clin Med. 2025; 13(24.
PMID: 39768760
PMC: 11678552.
DOI: 10.3390/jcm13247837.
West D, Stepney S, Hancock Y
Sci Rep. 2025; 15(1):773.
PMID: 39755726
PMC: 11700215.
DOI: 10.1038/s41598-024-83708-6.
Figueira M, Marques R, Cardoso H, Fonseca L, Duarte A, Silvestre S
Int J Mol Sci. 2024; 25(22).
PMID: 39596074
PMC: 11593390.
DOI: 10.3390/ijms252212006.
Cyr D, Adam C, Dufresne J, Gregory M
Cell Tissue Res. 2024; 398(3):191-206.
PMID: 39412535
DOI: 10.1007/s00441-024-03919-1.
The Protective Effects of an Aged Black Garlic Water Extract on the Prostate.
Libero M, Montero-Hidalgo A, Recinella L, Luque R, Generali D, Acquaviva A
Nutrients. 2024; 16(17).
PMID: 39275340
PMC: 11396974.
DOI: 10.3390/nu16173025.
Comparative Study of Essential Oils from Tunisian Mill. by Hydrodistillation and Microwave-Assisted Processes: Chemical Composition and Antioxidant and Cytotoxic Potential against Prostate and Cervical Cancer Cells.
Hamzaoui E, Zallez O, Bunay J, Leremboure M, Argui H, Baron S
ACS Omega. 2024; 9(31):34128-34139.
PMID: 39130574
PMC: 11308029.
DOI: 10.1021/acsomega.4c05123.
Therapeutic Effects of Essential Oils and Their Bioactive Compounds on Prostate Cancer Treatment.
Pimentel L, Bastos L, Goulart L, Ribeiro L
Pharmaceutics. 2024; 16(5).
PMID: 38794244
PMC: 11125265.
DOI: 10.3390/pharmaceutics16050583.
The Effect of HMGB1 and HMGB2 on Transcriptional Regulation Differs in Neuroendocrine and Adenocarcinoma Models of Prostate Cancer.
Salamini-Montemurri M, Vizoso-Vazquez A, Barreiro-Alonso A, Lorenzo-Catoira L, Rodriguez-Belmonte E, Cerdan M
Int J Mol Sci. 2024; 25(6).
PMID: 38542079
PMC: 10969884.
DOI: 10.3390/ijms25063106.
Inferring Drug Set and Identifying the Mechanism of Drugs for PC3.
Kim S
Int J Mol Sci. 2024; 25(2).
PMID: 38255837
PMC: 10815650.
DOI: 10.3390/ijms25020765.
Reduction in Nuclear Size by DHRS7 in Prostate Cancer Cells and by Estradiol Propionate in DHRS7-Depleted Cells.
Rizzotto A, Tollis S, Pham N, Zheng Y, Abad M, Wildenhain J
Cells. 2024; 13(1).
PMID: 38201261
PMC: 10778050.
DOI: 10.3390/cells13010057.
The use of beta-sitosterol for the treatment of prostate cancer and benign prostatic hyperplasia.
Macoska J
Am J Clin Exp Urol. 2023; 11(6):467-480.
PMID: 38148931
PMC: 10749388.
Generating a Murine PTEN Null Cell Line to Discover the Key Role of p110β-PAK1 in Castration-Resistant Prostate Cancer Invasion.
Wang H, Zhou Y, Chu C, Xiao J, Zheng S, Korpal M
Mol Cancer Res. 2023; 21(12):1317-1328.
PMID: 37606694
PMC: 10841189.
DOI: 10.1158/1541-7786.MCR-22-0808.
A role for androgen receptor variant 7 in sensitivity to therapy: Involvement of IGFBP-2 and FOXA1.
Biernacka K, Barker R, Sewell A, Bahl A, Perks C
Transl Oncol. 2023; 34:101698.
PMID: 37307644
PMC: 10276180.
DOI: 10.1016/j.tranon.2023.101698.
NALCN-mediated sodium influx confers metastatic prostate cancer cell invasiveness.
Folcher A, Gordienko D, Iamshanova O, Bokhobza A, Shapovalov G, Kannancheri-Puthooru D
EMBO J. 2023; 42(13):e112198.
PMID: 37278161
PMC: 10308360.
DOI: 10.15252/embj.2022112198.
Characterisation of cell lines derived from prostate cancer patients with localised disease.
Moya L, Walpole C, Rae F, Srinivasan S, Seim I, Lai J
Prostate Cancer Prostatic Dis. 2023; 26(3):614-624.
PMID: 37264224
PMC: 10449630.
DOI: 10.1038/s41391-023-00679-x.
Structures of Mammeasins P and Q, Coumarin-Related Polysubstituted Benzofurans, from the Thai Medicinal Plant (Miq.) T. Anders.: Anti-Proliferative Activity of Coumarin Constituents against Human Prostate Carcinoma Cell Line LNCaP.
Luo F, Manse Y, Chaipech S, Pongpiriyadacha Y, Muraoka O, Morikawa T
Pharmaceuticals (Basel). 2023; 16(2).
PMID: 37259379
PMC: 9966789.
DOI: 10.3390/ph16020231.
Anti-cancer potential of synergistic phytochemical combinations is influenced by the genetic profile of prostate cancer cell lines.
Gano C, Fatima S, Failes T, Arndt G, Sajinovic M, Mahns D
Front Nutr. 2023; 10:1119274.
PMID: 36960209
PMC: 10029761.
DOI: 10.3389/fnut.2023.1119274.
Preclinical models of prostate cancer - modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo.
Germain L, Lafront C, Paquette V, Neveu B, Paquette J, Pouliot F
Nat Rev Urol. 2023; 20(8):480-493.
PMID: 36788359
DOI: 10.1038/s41585-023-00726-1.
The future of patient-derived xenografts in prostate cancer research.
Lawrence M, Taylor R, Cuffe G, Ang L, Clark A, Goode D
Nat Rev Urol. 2023; 20(6):371-384.
PMID: 36650259
PMC: 10789487.
DOI: 10.1038/s41585-022-00706-x.
